WuXi AppTec Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
39,414
- Stock Symbol
-
603259
- Investments
-
81
- Share Price
-
$7.09
- (As of Wednesday Closing)
WuXi AppTec General Information
Description
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by China, Europe, and other regions.
Contact Information
Website
www.wuxiapptec.comCorporate Office
- 288 Fute Zhong Road
- Waigaoqiao Free Trade Zone, Pudong New Area
- Shanghai, 200131
- China
Corporate Office
- 288 Fute Zhong Road
- Waigaoqiao Free Trade Zone, Pudong New Area
- Shanghai, 200131
- China
WuXi AppTec Stock Performance
As of 16-Apr-2025, WuXi AppTec’s stock price is $7.09. Its current market cap is $20.3B with 2.89B shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $7.09 | $7.21 | $5.00 - $9.78 | $20.3B | 2.89B | 44.8M | $0.46 |
WuXi AppTec Financials Summary
As of 31-Dec-2024, WuXi AppTec has a trailing 12-month revenue of $5.47B.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 20,736,150 | 20,736,150 | 29,537,211 | 33,526,240 |
| Revenue | 5,468,838 | 5,468,838 | 5,701,978 | 5,843,722 |
| EBITDA | 1,938,728 | 1,938,728 | 1,939,919 | 1,815,804 |
| Net Income | 1,317,032 | 1,317,032 | 1,357,867 | 1,308,733 |
| Total Assets | 11,003,387 | 11,003,387 | 10,392,652 | 9,376,361 |
| Total Debt | 686,135 | 686,135 | 810,832 | 850,295 |
WuXi AppTec Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
WuXi AppTec Comparisons
Industry
Financing
Details
WuXi AppTec Competitors (55)
One of WuXi AppTec’s 55 competitors is BGI Genomics, a Formerly VC-backed company based in Shenzhen, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BGI Genomics | Formerly VC-backed | Shenzhen, China | ||||
| Pharmaron | Formerly VC-backed | Beijing, China | ||||
| Charles River Laboratories International | Formerly PE-Backed | Wilmington, MA | ||||
| Inotiv | Formerly PE-Backed | West Lafayette, IN | ||||
| Syngene International | Formerly PE-Backed | Bangalore, India |
WuXi AppTec Patents
WuXi AppTec Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210085677-A1 | Shp2 phosphatase inhibitors and methods of making and using the same | Active | 24-Sep-2019 | ||
| US-11890281-B2 | Shp2 phosphatase inhibitors and methods of making and using the same | Active | 24-Sep-2019 | ||
| US-20240122925-A1 | Shp2 phosphatase inhibitors and methods of making and using the same | Pending | 24-Sep-2019 | ||
| US-20220048888-A1 | Pyrimidinyl-heteroaryloxy-naphthyl compounds and methods of use | Pending | 12-Sep-2018 | ||
| US-10968203-B2 | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | Active | 17-Mar-2017 | C07D413/14 |
WuXi AppTec Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
WuXi AppTec Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
WuXi AppTec Investments & Acquisitions (81)
WuXi AppTec’s most recent deal was a Early Stage VC with D3 Bio for . The deal was made on 08-Apr-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| D3 Bio | 08-Apr-2024 | Early Stage VC | Biotechnology | ||
| Bioyond Technology | 23-Feb-2023 | Early Stage VC | Diagnostic Equipment | ||
| Wisdo Health | 05-Jan-2023 | Later Stage VC | Social/Platform Software | ||
| Structure Therapeutics | 01-Aug-2022 | Later Stage VC | Drug Discovery | ||
| ConjuStar | 20-Feb-2022 | Joint Venture | Drug Discovery |
WuXi AppTec ESG
Risk Overview
Risk Rating
Updated May, 31, 2024
10.88 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Pharmaceuticals
Industry
of 861
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 60
Rank
Percentile
WuXi AppTec Exits (27)
WuXi AppTec’s most recent exit was on 01-Aug-2022 from Structure Therapeutics. The exit was categorized as with 22 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Structure Therapeutics | 01-Aug-2022 | Completed |
|
||
| CANbridge Pharma | 21-May-2021 | Completed |
|
||
| Ambrx | 03-Nov-2020 | Completed |
|
||
| JW Therapeutics | 03-Jun-2020 | Completed |
|
||
| Lyell Immunopharma | 05-Mar-2020 | Later Stage VC | Completed |
|
WuXi AppTec Affiliates
Subsidiaries (9)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| WuXi (15,520 Square Meter Vaccine Plant in Dundalk, Ireland) | Dundalk, Ireland | 2019 | |
| WuXi Clinical Development Services (Shanghai) Co. | Shanghai, China | 2013 | |
| Pharmapace | San Diego, CA | 2013 | |
| Oxgene | Oxford, United Kingdom | 2011 | |
| Crelux | Martinsried, Germany | 2005 |
WuXi AppTec FAQs
-
When was WuXi AppTec founded?
WuXi AppTec was founded in 2000.
-
Where is WuXi AppTec headquartered?
WuXi AppTec is headquartered in Shanghai, China.
-
What is the size of WuXi AppTec?
WuXi AppTec has 39,414 total employees.
-
What industry is WuXi AppTec in?
WuXi AppTec’s primary industry is Discovery Tools (Healthcare).
-
Is WuXi AppTec a private or public company?
WuXi AppTec is a Public company.
-
What is WuXi AppTec’s stock symbol?
The ticker symbol for WuXi AppTec is 603259.
-
What is the current stock price of WuXi AppTec?
As of 16-Apr-2025 the stock price of WuXi AppTec is $7.09.
-
What is the current market cap of WuXi AppTec?
The current market capitalization of WuXi AppTec is $20.3B.
-
What is WuXi AppTec’s current revenue?
The trailing twelve month revenue for WuXi AppTec is $5.47B.
-
Who are WuXi AppTec’s competitors?
BGI Genomics, Pharmaron, Charles River Laboratories International, Inotiv, and Syngene International are some of the 55 competitors of WuXi AppTec.
-
What is WuXi AppTec’s annual earnings per share (EPS)?
WuXi AppTec’s EPS for 12 months was $0.46.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
